Study of SYS6020 for active lupus
Part of Immune system & allergy clinical trials.
This trial tests a new medicine called SYS6020 for people whose lupus is still active despite standard treatments. It aims to see if the drug can help reduce lupus activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with systemic lupus erythematosus (SLE) using standard criteria.
- You have taken steroids with other immune-suppressing medicines or biologics for at least 3 months, at a stable dose for 2 weeks, but your lupus is still active.
- You have certain lupus antibodies in your blood (like ANA, anti-dsDNA, or anti-Smith).
- Your lupus activity score (SLEDAI-2K) is 7 or higher, and you have moderate to severe organ involvement.
- You do not have severe lupus kidney disease, lupus affecting the brain, or other serious conditions listed in the exclusion criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called ACG102, given as an injection, for people with active lupus that hasn't improved with standard treatments. The goal is to see if it can help control the disease and reduce symptoms.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This trial tests a new treatment called ACE1831 for people with moderate to severe lupus that has not improved with standard treatments like steroids or other medications. The goal is to see if it can help control lupus activity.
Hear when a new Refractory Active Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.